415 Capital
Munich, Bavaria415capital.com
Overview
415 Capital is a specialist venture capital firm dedicated to investing in breakthrough and life-saving medical innovation. They invest in early- and development-stage MedTech companies in Europe, the United States and Israel. They primarily invest in innovative medical device technologies addressing cardiovascular and neurovascular diseases.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Endovascular Engineering, Inc. | Apr 2026 | Series C | Co-investor |
| Supira Medical | Mar 2025 | Series E | Co-investor |
| Endovascular Engineering, Inc. | Feb 2025 | Series B | Lead |
| CorFlow Therapeutics AG | Sep 2024 | Series B | Co-investor |
| R3 Vascular Inc. | May 2024 | Series B | Co-investor |
Key People
David P. Thompson
Co-Founder General Partner
Azin Parhizgar
Sr Venture Partner
Michael Braun
Senior Venture Partner
Rob Michiels
Senior Venture Partner
Linus Rieder
Principal
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
